AOD-9604 came from a clever idea: take the part of growth hormone that burns fat, and leave the rest behind. Growth hormone does many things in the body, but its fat-mobilizing power lives in one specific region of the molecule. AOD-9604 isolates exactly that region, making it one of the most targeted fat-metabolism compounds ever studied.
What AOD-9604 is
AOD-9604 is a synthetic peptide based on the tail end of human growth hormone, specifically the segment corresponding to amino acids 176 to 191. Researchers identified this short stretch as the part of growth hormone responsible for much of its fat-reducing activity. To create AOD-9604, scientists at the Australian company Metabolic Pharmaceuticals (with roots in research at Monash University) took that natural fragment and added a tyrosine residue to one end, improving its stability. The name itself reflects its purpose: AOD stands for Anti-Obesity Drug.
What the research shows
The appeal of AOD-9604 is its selectivity. In preclinical research, it stimulated lipolysis, the breakdown of stored fat, while also reducing lipogenesis, the formation of new fat. Work by Heffernan and colleagues around 2000 and 2001 documented increased fat oxidation and lipolysis in animal models, with weight gain attenuated in obese animals. Critically, it did this without the broader effects of full growth hormone: it did not raise IGF-1 or disturb blood sugar, which is what makes it so attractive as a focused tool for studying fat metabolism specifically.
AOD-9604 has also been studied extensively in humans for safety. Across several Phase 1 and Phase 2 clinical trials involving hundreds of participants, it demonstrated a strong safety and tolerability profile, with no serious adverse events attributed to the compound. That clean safety record across substantial human testing is one of its most notable features, even though the weight-loss efficacy signals in those human trials were mixed across different protocols.
How it works
AOD-9604 targets fat cells directly. Rather than acting through the main growth hormone receptor, its fat-metabolizing effects are considered largely receptor-independent, with beta-3 adrenergic signalling implicated in preclinical models. By encouraging fat cells to release and oxidize stored fat while discouraging new fat storage, it shifts the balance of fat metabolism toward breakdown. Because it sidesteps the growth and insulin pathways that full growth hormone activates, it produces this fat-focused effect without the wider systemic changes, which is the entire reason the fragment was isolated in the first place.
Quick facts
| AOD-9604 | |
|---|---|
| Type | Synthetic fragment of human growth hormone (176-191) |
| Origin | Metabolic Pharmaceuticals / Monash, Australia |
| Best known for | Selective fat-metabolism research |
| Key mechanism | Stimulates lipolysis, reduces lipogenesis |
| Key advantage | No IGF-1 or blood sugar effects |
| Safety | Strong tolerability across human trials |
| Form | Lyophilized powder, reconstituted before use |
The bottom line
AOD-9604 represents one of the most precise approaches to fat metabolism in peptide science: it captures growth hormone’s fat-burning region while leaving its growth and insulin effects aside. Combined with a well-documented safety profile from human testing, that selectivity is what has kept it a compound of interest in metabolic research. To explore the metabolic peptides currently driving the biggest results, see the guides on Tirzepatide and Retatrutide.
References
- Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology, 2001.
- Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by the C-terminal fragment of human growth hormone. AJP-Endocrinology and Metabolism, 2000-2001.
- AOD-9604 human safety and tolerability across Phase 1 and 2 clinical trials (obesity pharmacotherapy literature).
For laboratory and research use only.